New PHE Study Released on Cost of Nonadherence
A novel approach to measuring the cost of nonadherence is outlined in a new article by Precision experts Jason Shafrin, Ross Maclean, and colleagues. The authors report findings of an adherence-exposure-outcome model simulation on the impact of nonadherence on progression-free survival in Cancer Management and Research.
To read the complete article as it appears in the publication, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.